Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) traded up 0.8% during trading on Monday . The stock traded as high as C$4.98 and last traded at C$4.96. 3,336 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 15,710 shares. The stock had previously closed at C$5.00.
Several equities research analysts recently commented on the company. TD Securities lifted their price objective on Cipher Pharmaceuticals from C$5.50 to C$6.50 in a report on Monday, August 14th. Bloom Burton downgraded Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 14th.
In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin acquired 35,000 shares of Cipher Pharmaceuticals stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average cost of C$4.69 per share, for a total transaction of C$164,150.00.
ILLEGAL ACTIVITY WARNING: “Cipher Pharmaceuticals (CPH) Trading -0.8% Higher” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/cipher-pharmaceuticals-cph-trading-0-8-higher.html.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.